**Supplementary Table S5:** Classification of hr-HPV subtypes according to positive predictive value for CIN2+ based on single- and multiple-type infections

|  |  |  |
| --- | --- | --- |
|  **hr-HPV Type** |  | **Cumulative** |
|  | **N at risk\*** | **CIN2+/hr-HPV+** | **PPV** | **Sensitivity** | **Specificity** |
| **Provider-collected samples** |
|  **HPV-16** | 314 | 34/62 | 54.8% | 40.0% | 87.8% |
|  **HPV-33/58** | 252 | 9/20 | 45.0% | 50.6% | 83.0% |
|  **HPV-51** | 232 | 6/16 | 37.5% | 57.6% | 78.6% |
|  **HPV-31** | 216 | 7/18 | 38.9% | 65.9% | 73.8% |
|  **HPV-52** | 198 | 9/25 | 36.0% | 76.5% | 66.8% |
|  **HPV-35/39/68** | 173 | 8/27 | 29.6% | 85.9% | 58.5% |
|  **HPV-45** | 146 | 2/12 | 16.7% | 88.2% | 54.1% |
|  **HPV-56/59/66** | 134 | 5/33 | 15.2% | 94.1% | 41.9% |
|  **HPV-18** | 101 | 0/7 | 0.0% | 94.1% | 38.9% |
| **Self-collected samples** |
|  **HPV-16** | 314 | 39/85 | 45.9% | 45.9% | 79.9% |
|  **HPV-51** | 229 | 6/15 | 40.0% | 52.9% | 76.0% |
|  **HPV-33/58** | 214 | 8/21 | 38.1% | 62.4% | 70.3% |
|  **HPV-31** | 193 | 8/23 | 34.8% | 71.8% | 63.8% |
|  **HPV-52** | 170 | 7/23 | 30.4% | 80.0% | 56.8% |
|  **HPV-18** | 147 | 3/10 | 30.0% | 83.5% | 53.7% |
|  **HPV-56/59/66†** | 137 | 4/26 | 15.4% | 85.9% | 43.2% |
|  **HPV-45†** | 137 | 2/13 | 15.4% | 88.2% | 38.4% |
|  **HPV-35/39/68** | 98 | 4/23 | 17.4% | 92.9% | 30.1% |

CIN2+: cervical intraepithelial neoplasia grade 2 or higher; hr-HPV: high-risk human papillomavirus; PPV: positive predictive value.

\*Includes women with single- and multiple-type hr-HPV infections; PPVs were calculated for women who did not have one of the already selected genotypes.

† These genotypes had the same PPVs for detection of CIN2+